No doubt. What i was hoping for is more progress on the rest of the company, M118, oncology, other programs with nvs, etc to bump up the downside base value. As far as approval, i know of no way to discount the outcome. It's not like an NDA where you can check the boxes, efficacy, side effects, need.
Dew, if one of the worst case scenarios unfolds and MNTA is asked to run a trial comparing its generic Lovenox to the branded one, has it been spelled out how the expenses of such a trial would be split with NVS? Would NVS be responsible for all such costs or would there be a split with MNTA?
Market Data 
Markets 
AI
